Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss? BY Vandana Singh • September 17, 2025September 17, 2025 Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a wei[...] Read more
